| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/23/2009 | US20090105632 Electrotransport Of Lisuride |
| 04/23/2009 | US20090105478 Novel compounds |
| 04/23/2009 | US20090105348 Treatment of migraine headaches using antiestrogens |
| 04/23/2009 | US20090105345 AMIDE LINKED MODULATORS OF Gamma-SECRETASE |
| 04/23/2009 | US20090105344 Biphenyl carboxylic acids and derivatives thereof |
| 04/23/2009 | US20090105342 Pufa supplements |
| 04/23/2009 | US20090105340 Composition and/or method for preventing recurrence of stroke |
| 04/23/2009 | US20090105334 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/23/2009 | US20090105327 Dibenzocycloheptane compounds and pharmaceuticals containing these compounds |
| 04/23/2009 | US20090105318 Amidoethylthioether Orexin Receptor Antagonists |
| 04/23/2009 | US20090105307 2-aminooxazolines as taar1 ligands |
| 04/23/2009 | US20090105306 Novel compounds as cannabinoid receptor ligands |
| 04/23/2009 | US20090105304 Combination therapy for reducing side effects using cannabinoid receptor ligands |
| 04/23/2009 | US20090105300 AMINE LINKED MODULATORS OF y-SECRETASE |
| 04/23/2009 | US20090105298 Pharmaceutical composition for therapy of interstitial cystitis |
| 04/23/2009 | US20090105291 Ethyl (2S)-2-[(4,4-dimethyl-3-oxo-1-cyclobutenyl)amino]-3-[(4-([2,7]naphthyridin-1-yloxy)phenyl]propanoate; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders |
| 04/23/2009 | US20090105288 CARBON LINKED MODULATORS OF gamma-SECRETASE |
| 04/23/2009 | US20090105281 Methods of treating inflammation |
| 04/23/2009 | US20090105275 PIPERIDINYL AND PIPERAZINYL MODULATORS OF y-SECRETASE |
| 04/23/2009 | US20090105269 Multifunctional Compounds and Methods of Use Thereof |
| 04/23/2009 | US20090105267 Octahydro-pyrrolo[3,4-b]pyrrole n-oxides |
| 04/23/2009 | US20090105261 Novel substituted pyrazolo[1,5<I>A</I>]-1,3,5-Triazine derivatives and their analogues, pharmaceutical compositions containing same, use thereof as medicine and methods for preparing same |
| 04/23/2009 | US20090105257 Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| 04/23/2009 | US20090105252 Pyrimidine Derivatives and Their Use in Therapy as well as the Use of Pyrimidine Derivatives in the Manufacture of a Medicament for Prevention and/or Treatment of Alzheimer's Disease |
| 04/23/2009 | US20090105231 Amide derivatives as rock inhibitors |
| 04/23/2009 | US20090105229 Purine derivatives as kinase inhibitors |
| 04/23/2009 | US20090105228 Heterocyclic benzodiazepine cgrp receptor antagonists |
| 04/23/2009 | US20090105226 administering 7-Benzyloxy-3-cyclobutyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine, for the treatment of Alzheimer's disease, cognitive impairment, dementia, epilepsy, neuropathic pain, Parkinson's disease, schizophrenia, attention deficit disorder or depression in humans |
| 04/23/2009 | US20090105224 Tetrahydrobenzazepines and their use in the modulation of the dopamine d3 receptor |
| 04/23/2009 | US20090105222 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 04/23/2009 | US20090105218 CRTH2 Receptor Ligands For Therapeutic Use |
| 04/23/2009 | US20090105217 2-phenyl-5-amino-1,3,4-oxadiazoles and their use as nicotinic acetylcholine receptor ligands |
| 04/23/2009 | US20090105215 Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
| 04/23/2009 | US20090105208 Substituted Piperazines as CB1 Antagonists |
| 04/23/2009 | US20090105197 Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Analgesia Synergistically in Mammals |
| 04/23/2009 | US20090105189 Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same |
| 04/23/2009 | US20090105169 Allele-specific silencing of disease genes |
| 04/23/2009 | US20090105159 Neuroprotective Compounds and Uses Thereof |
| 04/23/2009 | US20090105156 Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| 04/23/2009 | US20090105152 Metastin derivatives and use thereof |
| 04/23/2009 | US20090105141 Intraventricular protein delivery for amyotrophic lateral sclerosis |
| 04/23/2009 | US20090104697 Method of differentiation of morula or inner cell mass cells and method of making lineage-defective embryonic stem cells |
| 04/23/2009 | US20090104283 Method for reducing the severity of neurological disorders |
| 04/23/2009 | US20090104266 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation |
| 04/23/2009 | US20090104261 Treatment for Attention-Deficit Hyperactivity Disorder |
| 04/23/2009 | US20090104230 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/23/2009 | US20090104206 Bone microenvironment modulated migraine treatments |
| 04/23/2009 | US20090104200 Modulating inflammasome activity and inflammation in the central nervous system |
| 04/23/2009 | US20090104171 Metabolic Enhancement Therapy |
| 04/23/2009 | US20090104142 Compositions for treating multiple sclerosis |
| 04/23/2009 | CA2703636A1 Amine linked modulators of .gamma.-secretase |
| 04/23/2009 | CA2703425A1 Tetrazole derivatives as modulators of metabotropic glutamate receptors (mglurs) |
| 04/23/2009 | CA2702959A1 Carbon linked modulators of .gamma.-secretase |
| 04/23/2009 | CA2702958A1 Method for producing pyrazole fused ring derivative |
| 04/23/2009 | CA2702950A1 Methods and compounds for modulating cannabinoid activity |
| 04/23/2009 | CA2702880A1 Antibody capable of specifically binding to a beta oligomer, and use thereof |
| 04/23/2009 | CA2702837A1 Piperidinyl and piperazinyl modulators of .gamma.-secretase |
| 04/23/2009 | CA2702835A1 Amide linked modulators of .gamma.-secretase |
| 04/23/2009 | CA2702834A1 Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof |
| 04/23/2009 | CA2702832A1 Biphenyl carboxylic acids and derivatives thereof |
| 04/23/2009 | CA2702680A1 Combination analgesic employing opioid and neutral antagonist |
| 04/23/2009 | CA2702664A1 Controlled-release pharmaceutical formulation |
| 04/23/2009 | CA2702644A1 A3 adenosine receptor antagonists |
| 04/23/2009 | CA2702634A1 Compositions for treating multiple sclerosis |
| 04/23/2009 | CA2702617A1 Immunotherapy regimes dependent on apoe status |
| 04/23/2009 | CA2702524A1 Heterocycle-substituted piperazino-dihydrothienopyrimidines |
| 04/23/2009 | CA2702494A1 Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss |
| 04/23/2009 | CA2702468A1 Therapeutic applications of fatty acid amide hydrolase inhibitors |
| 04/23/2009 | CA2702455A1 Therapeutic agent for trpv1-mediated disease |
| 04/23/2009 | CA2700910A1 Combination therapy for reducing side effects using cannabinoid receptor ligands |
| 04/23/2009 | CA2700648A1 Quinolizidinone m1 receptor positive allosteric modulators |
| 04/23/2009 | CA2699075A1 Use of a peptide as a therapeutic agent |
| 04/23/2009 | CA2697982A1 1,3,5-trisubstituted triazole derivative |
| 04/23/2009 | CA2697974A1 Trisubstituted 1,2,4-triazoles |
| 04/23/2009 | CA2694994A1 Tricyclic n-heteroaryl-carboxamide derivatives, preparation thereof and therapeutic use of same |
| 04/23/2009 | CA2694377A1 Imidazolone derivatives, preparation method thereof and biological use of same |
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050751A1 Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| 04/22/2009 | EP2050750A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 04/22/2009 | EP2050741A1 Crystalline polymorphism of 5-methyl-2-(piperazin-1-yl)benzenesulfonic acid |
| 04/22/2009 | EP2050739A1 Quinazoline derivative |
| 04/22/2009 | EP2050737A1 Mono-and divalent salts of n-(5-hydroxynicotinoil)-l-glutaminic acid exhibiting psychotropic (antidepressant and anxyolytic), neuroprotective, heroprotective and cerebroprotective action |
| 04/22/2009 | EP2050736A1 Imidazole derivatives, processes for preparing them and their uses |
| 04/22/2009 | EP2050453A1 Pharmaceutical combinations of meloxicam, tramadol and paracetamol |
| 04/22/2009 | EP2050451A1 3,11b cis dihydrotetrabanezine for the treatment of psychoses |
| 04/22/2009 | EP2050450A1 1-Piperidine-2-cyanoimino-1,3-dihydro-2H-benzimidazole derivatives as nociceptin analogs with ORL1 modulating activity for the treatment of pain |
| 04/22/2009 | EP2049548A1 Fused oxazoles & thiazoles as histamine h3- receptor ligands |
| 04/22/2009 | EP2049538A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use |
| 04/22/2009 | EP2049532A1 Cgrp receptor antagonists |
| 04/22/2009 | EP2049529A1 Substituted diazepan orexin receptor antagonists |
| 04/22/2009 | EP2049525A1 N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof |
| 04/22/2009 | EP2049516A2 Pharmaceutical compounds |
| 04/22/2009 | EP2049485A1 Naphthalene derivatives used as ep4 receptor agonists |
| 04/22/2009 | EP2049483A2 Inhibitors of histone deacetylase |
| 04/22/2009 | EP2049478A1 Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use |
| 04/22/2009 | EP2049473A2 Substituted benzyl amine compounds |
| 04/22/2009 | EP2049472A2 Cyclopropyl amine derivatives as histamin h3 receptor modulators |
| 04/22/2009 | EP2049466A1 Butyl and butynyl benzyl amine compounds |
| 04/22/2009 | EP2049146A2 Use of proteins of the sdf-1-family for for improvement of axonal plasticity or for axonal regeneration following lesions |
| 04/22/2009 | EP2049133A2 New eucalyptus extract, method of preparation and therapeutic uses thereof |